1. Couser WG. Primary Membranous Nephropathy. Clin J Am Soc Nephrol 2017;12:983-97.
2. Debiec H, Guigonis V, Mougenot B, et al. Antenatal membranous glomerulonephritis due to anti-neutral endopeptidase antibodies. N Engl J Med 2002;346:2053-60.
3. Beck LH Jr, Bonegio RG, Lambeau G, et al. M-type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy. N Engl J Med 2009;361:11-21.
4. Hanset N, Aydin S, Demoulin N, et al. Podocyte antigen staining to identify distinct phenotypes and outcomes in membranous nephropathy: a retrospective multicenter cohort study. Am J Kidney Dis 2020;76:624-35.
5. Sethi S, Debiec H, Madden B, et al. Semaphorin 3B-associated membranous nephropathy is a distinct type of disease predominantly present in pediatric patients. Kidney Int 2020;98:1253-64.
6. Floege J, Barbour SJ, Cattran DC, et al. Management and treatment of glomerular diseases (part 1): conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) controversies conference. Kidney Int 2019;95:268-80.
7. Caza T, Hassen S, Dvanajscak Z, et al. NELL1 is a target antigen in malignancy-associated membranous nephropathy. Kidney Int 2020;S0085-2538(20)30956-X.
8. Gupta S, Köttgen A, Hoxha E, et al. Genetics of membranous nephropathy. Nephrol Dial Transplant 2018;33:1493-1502.
9. Dahan K, Debiec H, Plaisier E, et al. Rituximab for severe membranous nephropathy: a 6-month trial with extended follow-up. J Am Soc Nephrol 2017;28:348-58.
10. Fervenza FC, Appel GB, Barbour SJ, et al.Rituximab or Cyclosporine in the Treatment of Membranous Nephropathy. N Engl J Med 2019;381:36-46.